Incyte Corp. (INCY)
115.71
-1.22
(-1.04%)
USD |
NASDAQ |
Oct 23, 16:00
115.60
-0.11
(-0.10%)
After-Hours: 20:00
Incyte Price to Book Value : 3.665 for Oct. 23, 2026
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 3.665 |
| October 22, 2026 | 3.704 |
| October 21, 2026 | 3.594 |
| October 20, 2026 | 3.694 |
| October 19, 2026 | 3.588 |
| October 16, 2026 | 3.582 |
| October 15, 2026 | 3.588 |
| October 14, 2026 | 3.534 |
| October 13, 2026 | 3.441 |
| October 12, 2026 | 3.528 |
| October 09, 2026 | 3.573 |
| October 08, 2026 | 3.572 |
| October 07, 2026 | 3.594 |
| October 06, 2026 | 3.571 |
| October 05, 2026 | 3.615 |
| October 02, 2026 | 3.652 |
| October 01, 2026 | 3.711 |
| September 30, 2026 | 3.844 |
| September 29, 2026 | 3.903 |
| September 28, 2026 | 3.954 |
| September 25, 2026 | 3.925 |
| September 24, 2026 | 3.942 |
| September 23, 2026 | 3.948 |
| September 22, 2026 | 4.021 |
| September 21, 2026 | 3.949 |
| Date | Value |
|---|---|
| September 18, 2026 | 3.970 |
| September 17, 2026 | 4.043 |
| September 16, 2026 | 3.952 |
| September 15, 2026 | 3.856 |
| September 14, 2026 | 3.871 |
| September 11, 2026 | 3.848 |
| September 10, 2026 | 3.905 |
| September 09, 2026 | 3.992 |
| September 08, 2026 | 3.941 |
| September 04, 2026 | 4.015 |
| September 03, 2026 | 4.055 |
| September 02, 2026 | 4.081 |
| September 01, 2026 | 3.96 |
| August 31, 2026 | 3.903 |
| August 28, 2026 | 3.940 |
| August 27, 2026 | 4.046 |
| August 26, 2026 | 4.059 |
| August 25, 2026 | 4.109 |
| August 24, 2026 | 4.054 |
| August 21, 2026 | 4.049 |
| August 20, 2026 | 4.030 |
| August 19, 2026 | 4.070 |
| August 18, 2026 | 3.911 |
| August 17, 2026 | 3.912 |
| August 14, 2026 | 3.806 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Mirum Pharmaceuticals, Inc. | -- |
| Regeneron Pharmaceuticals, Inc. | 2.625 |
| AbbVie, Inc. | -- |
| Alnylam Pharmaceuticals, Inc. | 22.13 |
| Biogen, Inc. | 1.964 |
Price to Book Value Related Metrics
| PE Ratio | 14.75 |
| PS Ratio | 4.082 |
| PEG Ratio | 0.1881 |
| Price to Free Cash Flow | 12.57 |
| Price | 115.71 |
| Earnings Yield | 6.78% |
| Market Cap | 23.26B |
| PEGY Ratio | 0.1881 |
| Operating PE Ratio | 12.91 |
| Normalized PE Ratio | 14.52 |